The seroepidemiology of human T-lymphotropic viruses: Types I and II in Europe: A prospective study of pregnant women

Graham P. Taylor, Monique Bodéus, Françoise Courtois, Georg Pauli, Annarosa Del Mistro, Ana Machuca, Elizabeth Padua, Soren Andersson, Patrick Goubau, Luigi Chieco-Bianchi, Vincent Soriano, Joliette Coste, Anthony E. Ades, Jonathan N. Weber

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: Up to 20 million persons are infected with the human retroviruses human T-lymphotropic virus (HTLV)-I and HTLV-II globally. Most data on the seroprevalence of HTLV-I and HTLV-II in Europe are from studies of low-risk blood donors or high-risk injection drug users (IDUs). Little is known about the general population. Methods: A prospective anonymous study of HTLV-I and HTLV-II seroprevalence among 234,078 pregnant women in Belgium, France, Germany, Italy, Portugal, Spain, and the United Kingdom was conducted. Maternal antibody status was determined by standard methods using sera obtained for routine antenatal infection screens or eluted from infant heel prick dried blood spots obtained for routine neonatal metabolic screens. Results: Anti-HTLV-I/II antibodies were detected and confirmed in 96 pregnant women (4.4 per 10,000, 95% confidence interval [CI]: 3.5-5.2). Of these, 73 were anti-HTLV-I, 17 were anti-HTLV-II, and 6 were specifically anti-HTLV but untyped. The seroprevalence ranged from 0.7 per 10,000 in Germany to 11.5 per 10,000 in France. Conclusions: Pregnant women better reflect the general population than blood donors or IDUs. The seroprevalence of HTLV-I and HTLV-II in Western Europe is 6-fold higher among pregnant women (4.4 per 10,000) than among blood donors (0.07 per 10,000). These data provide a robust baseline against which changes in HTLV-I and HTLV-II seroprevalence in Europe can be measured.

Original languageEnglish
Pages (from-to)104-109
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume38
Issue number1
DOIs
Publication statusPublished - Jan 1 2005

Fingerprint

Human T-lymphotropic virus 2
Pregnant Women
Prospective Studies
Seroepidemiologic Studies
Viruses
Blood Donors
Drug Users
France
HTLV-II Antibodies
Germany
Injections
Portugal
Heel
Belgium
Retroviridae
Spain
Italy
Population
Mothers
Confidence Intervals

Keywords

  • Epidemiology
  • HTLV-I
  • HTLV-II
  • Pregnant women
  • Western Europe

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

The seroepidemiology of human T-lymphotropic viruses : Types I and II in Europe: A prospective study of pregnant women. / Taylor, Graham P.; Bodéus, Monique; Courtois, Françoise; Pauli, Georg; Del Mistro, Annarosa; Machuca, Ana; Padua, Elizabeth; Andersson, Soren; Goubau, Patrick; Chieco-Bianchi, Luigi; Soriano, Vincent; Coste, Joliette; Ades, Anthony E.; Weber, Jonathan N.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 38, No. 1, 01.01.2005, p. 104-109.

Research output: Contribution to journalArticle

Taylor, GP, Bodéus, M, Courtois, F, Pauli, G, Del Mistro, A, Machuca, A, Padua, E, Andersson, S, Goubau, P, Chieco-Bianchi, L, Soriano, V, Coste, J, Ades, AE & Weber, JN 2005, 'The seroepidemiology of human T-lymphotropic viruses: Types I and II in Europe: A prospective study of pregnant women', Journal of Acquired Immune Deficiency Syndromes, vol. 38, no. 1, pp. 104-109. https://doi.org/10.1097/00126334-200501010-00018
Taylor, Graham P. ; Bodéus, Monique ; Courtois, Françoise ; Pauli, Georg ; Del Mistro, Annarosa ; Machuca, Ana ; Padua, Elizabeth ; Andersson, Soren ; Goubau, Patrick ; Chieco-Bianchi, Luigi ; Soriano, Vincent ; Coste, Joliette ; Ades, Anthony E. ; Weber, Jonathan N. / The seroepidemiology of human T-lymphotropic viruses : Types I and II in Europe: A prospective study of pregnant women. In: Journal of Acquired Immune Deficiency Syndromes. 2005 ; Vol. 38, No. 1. pp. 104-109.
@article{1ea0fe5029ca44559f9fe83003379215,
title = "The seroepidemiology of human T-lymphotropic viruses: Types I and II in Europe: A prospective study of pregnant women",
abstract = "Background: Up to 20 million persons are infected with the human retroviruses human T-lymphotropic virus (HTLV)-I and HTLV-II globally. Most data on the seroprevalence of HTLV-I and HTLV-II in Europe are from studies of low-risk blood donors or high-risk injection drug users (IDUs). Little is known about the general population. Methods: A prospective anonymous study of HTLV-I and HTLV-II seroprevalence among 234,078 pregnant women in Belgium, France, Germany, Italy, Portugal, Spain, and the United Kingdom was conducted. Maternal antibody status was determined by standard methods using sera obtained for routine antenatal infection screens or eluted from infant heel prick dried blood spots obtained for routine neonatal metabolic screens. Results: Anti-HTLV-I/II antibodies were detected and confirmed in 96 pregnant women (4.4 per 10,000, 95{\%} confidence interval [CI]: 3.5-5.2). Of these, 73 were anti-HTLV-I, 17 were anti-HTLV-II, and 6 were specifically anti-HTLV but untyped. The seroprevalence ranged from 0.7 per 10,000 in Germany to 11.5 per 10,000 in France. Conclusions: Pregnant women better reflect the general population than blood donors or IDUs. The seroprevalence of HTLV-I and HTLV-II in Western Europe is 6-fold higher among pregnant women (4.4 per 10,000) than among blood donors (0.07 per 10,000). These data provide a robust baseline against which changes in HTLV-I and HTLV-II seroprevalence in Europe can be measured.",
keywords = "Epidemiology, HTLV-I, HTLV-II, Pregnant women, Western Europe",
author = "Taylor, {Graham P.} and Monique Bod{\'e}us and Fran{\cc}oise Courtois and Georg Pauli and {Del Mistro}, Annarosa and Ana Machuca and Elizabeth Padua and Soren Andersson and Patrick Goubau and Luigi Chieco-Bianchi and Vincent Soriano and Joliette Coste and Ades, {Anthony E.} and Weber, {Jonathan N.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/00126334-200501010-00018",
language = "English",
volume = "38",
pages = "104--109",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The seroepidemiology of human T-lymphotropic viruses

T2 - Types I and II in Europe: A prospective study of pregnant women

AU - Taylor, Graham P.

AU - Bodéus, Monique

AU - Courtois, Françoise

AU - Pauli, Georg

AU - Del Mistro, Annarosa

AU - Machuca, Ana

AU - Padua, Elizabeth

AU - Andersson, Soren

AU - Goubau, Patrick

AU - Chieco-Bianchi, Luigi

AU - Soriano, Vincent

AU - Coste, Joliette

AU - Ades, Anthony E.

AU - Weber, Jonathan N.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: Up to 20 million persons are infected with the human retroviruses human T-lymphotropic virus (HTLV)-I and HTLV-II globally. Most data on the seroprevalence of HTLV-I and HTLV-II in Europe are from studies of low-risk blood donors or high-risk injection drug users (IDUs). Little is known about the general population. Methods: A prospective anonymous study of HTLV-I and HTLV-II seroprevalence among 234,078 pregnant women in Belgium, France, Germany, Italy, Portugal, Spain, and the United Kingdom was conducted. Maternal antibody status was determined by standard methods using sera obtained for routine antenatal infection screens or eluted from infant heel prick dried blood spots obtained for routine neonatal metabolic screens. Results: Anti-HTLV-I/II antibodies were detected and confirmed in 96 pregnant women (4.4 per 10,000, 95% confidence interval [CI]: 3.5-5.2). Of these, 73 were anti-HTLV-I, 17 were anti-HTLV-II, and 6 were specifically anti-HTLV but untyped. The seroprevalence ranged from 0.7 per 10,000 in Germany to 11.5 per 10,000 in France. Conclusions: Pregnant women better reflect the general population than blood donors or IDUs. The seroprevalence of HTLV-I and HTLV-II in Western Europe is 6-fold higher among pregnant women (4.4 per 10,000) than among blood donors (0.07 per 10,000). These data provide a robust baseline against which changes in HTLV-I and HTLV-II seroprevalence in Europe can be measured.

AB - Background: Up to 20 million persons are infected with the human retroviruses human T-lymphotropic virus (HTLV)-I and HTLV-II globally. Most data on the seroprevalence of HTLV-I and HTLV-II in Europe are from studies of low-risk blood donors or high-risk injection drug users (IDUs). Little is known about the general population. Methods: A prospective anonymous study of HTLV-I and HTLV-II seroprevalence among 234,078 pregnant women in Belgium, France, Germany, Italy, Portugal, Spain, and the United Kingdom was conducted. Maternal antibody status was determined by standard methods using sera obtained for routine antenatal infection screens or eluted from infant heel prick dried blood spots obtained for routine neonatal metabolic screens. Results: Anti-HTLV-I/II antibodies were detected and confirmed in 96 pregnant women (4.4 per 10,000, 95% confidence interval [CI]: 3.5-5.2). Of these, 73 were anti-HTLV-I, 17 were anti-HTLV-II, and 6 were specifically anti-HTLV but untyped. The seroprevalence ranged from 0.7 per 10,000 in Germany to 11.5 per 10,000 in France. Conclusions: Pregnant women better reflect the general population than blood donors or IDUs. The seroprevalence of HTLV-I and HTLV-II in Western Europe is 6-fold higher among pregnant women (4.4 per 10,000) than among blood donors (0.07 per 10,000). These data provide a robust baseline against which changes in HTLV-I and HTLV-II seroprevalence in Europe can be measured.

KW - Epidemiology

KW - HTLV-I

KW - HTLV-II

KW - Pregnant women

KW - Western Europe

UR - http://www.scopus.com/inward/record.url?scp=19944426970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944426970&partnerID=8YFLogxK

U2 - 10.1097/00126334-200501010-00018

DO - 10.1097/00126334-200501010-00018

M3 - Article

C2 - 15608533

AN - SCOPUS:19944426970

VL - 38

SP - 104

EP - 109

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -